 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Molecular Tuberculosis Testing Can Distinguish Between Treatment Failure And ReinfectionAugust 7, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Molecular assays should be used to distinguish between ineffective tuberculosis therapy and TB reinfection, according to a new report. Annika Kruuner and colleagues at Tartu University in Tartu, Estonia and the Karolinska Institute in Stockholm, Sweden, "investigated the means by which drug resistance emerges among drug-susceptible Mycobacterium tuberculosis strains during antituberculosis therapy" in their study, published in Clinical Infectious Diseases ("Use of Molecular Techniques to Distinguish Between Treatment Failure and Exogenous Reinfection with Mycobacterium Tuberculosis," July 15, 2002; 35;(2)146-155). Apparent drug resistance is often the result of exogenous reinfection, which can be detected using restriction fragment-length polymorphism (RFLP) analysis, Kruuner and coauthors found. The researchers reviewed data from 11 pulmonary TB patients whose cases were recorded in the Estonian National Reference Laboratory archive. Each of the patients had ultimately failed to respond to TB therapy despite carrying initially drug-susceptible TB strains, according to the report. RFLP analysis using the IS6110 polymorphism, which acts as a genetic TB fingerprint, showed RFLP pattern shifts in all 11 patients, study data showed. These shifts indicated new infections with different M. tuberculosis strains. In six patients, the TB strain responsible for the original infection remained drug-susceptible. "Exogenous reinfection with drug-resistant M. tuberculosis may be misinterpreted as the emergence of drug resistance if molecular testing techniques are not used," Kruuner and colleagues warned. TB & Outbreaks Weekly 08.06.02; Michael Greer A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
